Lead optimisation
Hit to lead
Assay Development
Therapeutic area
  • Endocrine
  • Metabolic

Project Aim

To develop a humanised antibody to Netrin-1 for the treatment of osteolytic bone disease


An Anti-Netrin-1 therapeutic offers the potential to prevent the need for revision arthroplasty and prolong lifespans of prosthetic joints

Target Class

Laminin-like proteins



Current Status

Hit to Lead. Antibody characterisation and selection prior to humanisation

Intellectual Property

Initial filings with the opportunity to create a protective IPR portfolio


Licence or shared risk collaboration

Key Contact

  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email
    Please see our Privacy policy in relation to the personal data you submit to us through this page.
  • We would love to send you information about LifeArc news and events. Please let us know if you would like us to contact you by selecting one of the following options:
All Licensing Opportunities